In this issue:
EV-302: EV + pembrolizumab for untreated, advanced urothelial cancer
PD-L1 status in metastatic urothelial carcinoma treated with ICIs
TROPHY-U-01: sacituzumab govitecan in metastatic urothelial carcinoma
EV for unresectable/metastatic urothelial cancer
Bladder cancer care during COVID-19
Outcomes of delays to radical cystectomy
Neoadjuvant chemotherapy for variant histology MIBC undergoing cystectomy
Two radical cystectomies by one team in 1 day
HRQOL after bladder cancer diagnosis
PLND vs. ePLND during radical cystectomy
Please login below to download this issue (PDF)